Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease

被引:81
作者
Boddy, JL
Gal, S
Malone, PR
Harris, AL [1 ]
Wainscoat, JS
机构
[1] Univ Oxford, John Radcliffe Hosp, Weatherail Inst Mol Med, Canc Res UK, Oxford OX3 9DS, England
[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DS, England
[3] Royal Berkshire & Battle Hosp, Dept Urol, Reading, Berks, England
关键词
D O I
10.1158/1078-0432.CCR-04-1237
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this study was to determine the potential of cell-free DNA levels as a diagnostic marker for prostate cancer, having first established the effect that blood sample processing has on this measurement. Experimental Design: A total of 152 blood samples were collected prospectively from patients before their prostate biopsy and 25 from men in two distinct control groups. Blood was processed to yield three components: one-spin plasma (n = 68), two-spin plasma (n = 152), and serum (n = 56) samples. Results: Having established the effect of sample preparation on the measured DNA level, the more reliable two-spin plasma sample was used to determine the relationship between the DNA level and the presence of prostate cancer. Those patients with cancer (n = 78) had a significantly higher level of DNA compared with the control groups (P < 0.0001 and P < 0.0001). However, DNA levels in patients with a benign biopsy (n = 74) were significantly higher than the 78 patients confirmed to have cancer (P = 0.02). Conclusions: We conclude that the sample type used in the quantitation of cell-free DNA has an effect on the level reported. Elevated levels are present in the two-spin plasma samples of patients with prostate cancer compared with healthy controls but are not of diagnostic value during the management of prostate cancer.
引用
收藏
页码:1394 / 1399
页数:6
相关论文
共 27 条
[1]   Intra-individual variation of serum prostate specific antigen levels in men with benign prostate biopsies [J].
Boddy, JL ;
Dev, S ;
Pike, DJ ;
Malone, PR .
BJU INTERNATIONAL, 2004, 93 (06) :735-738
[2]   Prostate-specific antigen velocity and repeated measures of prostate-specific antigen [J].
Carter, HB ;
Pearson, JD .
UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) :333-&
[3]   Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination - Enhancement of specificity with free PSA measurements [J].
Catalona, WJ ;
Smith, DS ;
Ornstein, DK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18) :1452-1455
[4]  
Chiu RWK, 2001, CLIN CHEM, V47, P1607
[5]   Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate [J].
Fleshner, NE ;
OSullivan, M ;
Fair, WR .
JOURNAL OF UROLOGY, 1997, 158 (02) :505-508
[6]  
FLESNER NE, 1997, J UROLOGY, V158, P8
[7]  
Goessl C, 2000, CANCER RES, V60, P5941
[8]   Amplification of HSD17B1 and ERBB2 in primary breast cancer [J].
Gunnarsson, C ;
Ahnström, M ;
Kirschner, K ;
Olsson, B ;
Nordenskjöld, B ;
Rutqvist, LE ;
Skoog, L ;
Stål, O .
ONCOGENE, 2003, 22 (01) :34-40
[9]  
Jahr S, 2001, CANCER RES, V61, P1659
[10]  
Jerónimo C, 2002, UROLOGY, V60, P1131